3514 Background: LUR is a novel agent that exerts antitumor activity through inhibition of
trans-activated transcription and modulation of tumor microenvironment. Preclinical synergism/…

Background Depatuxizumab mafodotin (Depatux-M) is a tumor-specific antibody–drug conjugate
consisting of an antibody (ABT-806) directed against activated epidermal growth factor …

Whole-brain radiotherapy (WBRT) is the treatment backbone for many patients with brain
metastasis; however, its efficacy in preventing disease progression and the associated toxicity …

Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from a …

Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS)
in patients with glioblastoma (GBM), but previous studies suggest that patients with …

Background Context Spinal instability is an acknowledged complication of spinal metastases;
in spite of recent suggested criteria, it is not clearly defined in the literature. Purpose This …

Background Standard treatment for glioblastoma is radiation with concomitant and adjuvant
temozolomide for 6 cycles, although the optimal number of cycles of adjuvant temozolomide …

Glioblastomas (GBMs) are very aggressive tumors that are resistant to conventional chemo-
and radiotherapy. New molecular therapeutic strategies are required to effectively eliminate …

A high percentage of patients with brain metastases frequently develop neurocognitive
symptoms; however, understanding how brain metastasis co-opts the function of neuronal circuits …

Glioblastomas (GBM) are devastating tumors in which there has been little clinical improvement
in the last decades. New molecularly directed therapies are under development. EGFR …